TY - JOUR
T1 - Statistical analysis plan for the Dex-CSDH trial: a randomised, double-blind, placebo-controlled trial of a 2-week course of dexamethasone for adult patients with a symptomatic chronic subdural haematoma
AU - Allison, Annabel
AU - Edlmann, Ellie
AU - Kolias, Angelos G.
AU - Davis-Wilkie, Carol
AU - Mee, Harry
AU - Thelin, Eric P.
AU - Turner, Carole
AU - Hutchinson, Peter J.
AU - Bond, Simon
PY - 2019/12/10
Y1 - 2019/12/10
N2 - Abstract
Background
The incidence of chronic subdural haematoma (CSDH) is increasing. Although surgery remains the mainstay of management for symptomatic patients, uncertainty remains regarding the role of steroids. Hence, the Dex-CSDH trial was launched in the UK in 2015 aiming to determine whether, compared to placebo, dexamethasone can improve the 6-month functional outcome of patients with symptomatic CSDH by reducing the rate of surgical intervention and recurrence rate.
Methods and design
Dex-CSDH is a multi-centre, pragmatic, parallel group, double-blind, randomised trial assessing the clinical utility of a 2-week course of dexamethasone following a CSDH. Seven hundred fifty patients were randomised to either dexamethasone or placebo. The primary outcome is the modified Rankin Scale at 6 months which is dichotomised to favourable (a score of 0–3) versus unfavourable (a score of 4–6).
Conclusions
This paper and the accompanying additional material describe the statistical analysis plan for the trial.
Trial registration
ISRCTN, ISRCTN80782810. Registered on 7 November 2014. http://www.isrctn.com/ISRCTN80782810. EudraCT, 2014-004948-35. Registered on 20 March 2015.
AB - Abstract
Background
The incidence of chronic subdural haematoma (CSDH) is increasing. Although surgery remains the mainstay of management for symptomatic patients, uncertainty remains regarding the role of steroids. Hence, the Dex-CSDH trial was launched in the UK in 2015 aiming to determine whether, compared to placebo, dexamethasone can improve the 6-month functional outcome of patients with symptomatic CSDH by reducing the rate of surgical intervention and recurrence rate.
Methods and design
Dex-CSDH is a multi-centre, pragmatic, parallel group, double-blind, randomised trial assessing the clinical utility of a 2-week course of dexamethasone following a CSDH. Seven hundred fifty patients were randomised to either dexamethasone or placebo. The primary outcome is the modified Rankin Scale at 6 months which is dichotomised to favourable (a score of 0–3) versus unfavourable (a score of 4–6).
Conclusions
This paper and the accompanying additional material describe the statistical analysis plan for the trial.
Trial registration
ISRCTN, ISRCTN80782810. Registered on 7 November 2014. http://www.isrctn.com/ISRCTN80782810. EudraCT, 2014-004948-35. Registered on 20 March 2015.
UR - https://pearl.plymouth.ac.uk/context/pms-research/article/1497/viewcontent/s13063_019_3866_6.pdf
U2 - 10.1186/s13063-019-3866-6
DO - 10.1186/s13063-019-3866-6
M3 - Article
SN - 1745-6215
VL - 20
JO - Trials
JF - Trials
IS - 1
ER -